Compare Abeona Therapeutics Inc (ABEO) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Boston Scientific Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.67 (market cap $373.32M), while Boston Scientific Corporation trades at $44.63 (market cap $67.33B). The key difference: Boston Scientific Corporation is far larger — about 180.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | BSX | |
|---|---|---|
Market Cap | $373.32M | $67.33B |
Sector | Health | Health |
52-Week High | $7.23 | $108.14 |
52-Week Low | $4.17 | $42.68 |
Enterprise Value | $228.22M | $76.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Boston Scientific (BSX) trades at $45.30, showing modest daily gains of 0.35% amid a bearish technical trend. The company demonstrates strong fundamentals with consistent earnings beats, revenue growth from $12.7B in 2022 to $20.1B in 2025, and robust profitability margins. Recent news highlights a significant price decline from all-time highs, creating valuation opportunities despite competitive pressures in key segments like electrophysiology.
The investment outlook remains positive based on strong analyst consensus (88% buy ratings) and a $73.63 price target implying 63% upside. Key risks include growth deceleration in core products and market volatility. Fundamentals support long-term value, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
